What is a recommended tapering plan for a patient taking 15mg of mirtazapine (Remeron) for 6 months?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirtazapine 15mg Tapering Plan After 6 Months

For a patient on mirtazapine 15mg for 6 months, gradually reduce the dose rather than stopping abruptly, using a reduction of approximately 10% of the current dose every 1-2 weeks, which translates to decreasing from 15mg to 7.5mg for 1-2 weeks, then discontinuing. 1

Rationale for Gradual Tapering

  • The FDA label explicitly states that adverse reactions may occur upon discontinuation or dose reduction of mirtazapine, and recommends gradually reducing the dosage rather than stopping abruptly whenever possible 1
  • While mirtazapine has a relatively favorable discontinuation profile compared to SSRIs, withdrawal symptoms can still occur and should be minimized through gradual dose reduction 2, 3

Specific Tapering Protocol

Week 1-2:

  • Reduce from 15mg to 7.5mg once daily at bedtime 1
  • This represents a 50% reduction, which is reasonable given the relatively short duration of treatment (6 months) and low starting dose 4

Week 3-4:

  • If the patient tolerates the 7.5mg dose well without withdrawal symptoms, discontinue completely 1
  • Alternatively, if any withdrawal symptoms emerge, maintain 7.5mg for an additional 1-2 weeks before discontinuing 4

Monitoring During Tapering

  • Schedule follow-up appointments every 1-2 weeks during the taper to assess for withdrawal symptoms and return of depressive symptoms 5
  • Monitor specifically for: insomnia, anxiety, irritability, dizziness, nausea, headache, and mood changes 2, 6
  • Document baseline symptoms and functioning before initiating the taper 5

Managing Withdrawal Symptoms

  • If withdrawal symptoms occur at any dose reduction, return to the previous well-tolerated dose and attempt a slower taper with smaller reductions 5, 7
  • Consider extending the time between dose reductions to 3-4 weeks if needed 4
  • Short-term adjunctive medications may be used for specific symptoms (e.g., temporary sleep aids for insomnia) 5, 7

Important Considerations

  • The FDA recommends that dose changes should not be made in intervals of less than 1-2 weeks to allow sufficient time for evaluation of response 1
  • Mirtazapine's elimination half-life of 20-40 hours supports once-daily dosing and makes it suitable for gradual tapering 3, 8
  • Patient agreement and collaboration are essential—ensure the patient understands the plan and knows they can request slower tapering if withdrawal symptoms emerge 5

Common Pitfalls to Avoid

  • Do not abruptly discontinue: This can precipitate withdrawal symptoms and potential mood destabilization 5, 1
  • Do not use a fixed timeline: The taper must be adjusted based on individual response, not a predetermined schedule 5
  • Do not abandon the patient: If they struggle with the taper, consider pausing at a stable dose rather than pushing forward 5
  • Be prepared to slow the taper or temporarily return to a higher dose if significant withdrawal symptoms or return of depressive symptoms occur 4, 5

References

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Risperidone Tapering Schedule

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Tapering Aripiprazole

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.